Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Lotta Hansson"'
Autor:
Hanna M. Ingelman-Sundberg, Lisa Blixt, David Wullimann, Jinghua Wu, Yu Gao, Katie Healy, Sandra Muschiol, Gordana Bogdanovic, Mikael Åberg, Christian Kjellander, Alba Grifoni, Alessandro Sette, Soo Aleman, Puran Chen, Ola Blennow, Lotta Hansson, Hans-Gustaf Ljunggren, Margaret Sällberg Chen, Marcus Buggert, Anders Österborg
Publikováno v:
Haematologica, Vol 109, Iss 2 (2023)
Externí odkaz:
https://doaj.org/article/9a1da4f8fd3c4dac915c990f5c17df64
Autor:
Maria Andersson, Tom Aadrian Mulder, Kia Heimersson, Sonja Sönnert-Husa, Annika Giertz, Lotta Hansson, Claes Karlsson, Jeanette Lundin, Anders Österborg, Marzia Palma
Publikováno v:
HemaSphere, Vol 7, p e18051e0 (2023)
Externí odkaz:
https://doaj.org/article/f6e4e8fe0b524982a996952075108d37
Autor:
Maria Andersson, Hemming Johansson, Anders Österborg, Agneta Månsson-Broberg, Lotta Hansson, Marzia Palma
Publikováno v:
HemaSphere, Vol 7, p e28011bd (2023)
Externí odkaz:
https://doaj.org/article/23d76477eef84b0387e4be7393b66b8d
Autor:
Puran Chen, Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Gunnar Söderdahl, Anders Österborg, C.I. Edvard Smith, Jan Vesterbacka, David Wullimann, Angelica Cuapio, Mira Akber, Gordana Bogdanovic, Sandra Muschiol, Mikael Åberg, Karin Loré, Margaret Sällberg Chen, Marcus Buggert, Per Ljungman, Soo Aleman, Hans-Gustaf Ljunggren
Publikováno v:
EBioMedicine, Vol 94, Iss , Pp 104700- (2023)
Summary: Background: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. However, there is limited information available from prospective clinical trial cohorts with respect to long-term immunogenicity-related responses
Externí odkaz:
https://doaj.org/article/2329229490de4fbd80902984341b218f
Autor:
Angelica Cuapio, Caroline Boulouis, Iva Filipovic, David Wullimann, Tobias Kammann, Tiphaine Parrot, Puran Chen, Mira Akber, Yu Gao, Quirin Hammer, Benedikt Strunz, André Pérez Potti, Olga Rivera Ballesteros, Joshua Lange, Jagadeeswara Rao Muvva, Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Gunnar Söderdahl, Anders Österborg, C. I. Edvard Smith, Gordana Bogdanovic, Sandra Muschiol, Fredrika Hellgren, Karin Loré, Michal J. Sobkowiak, Giorgio Gabarrini, Katie Healy, Margaret Sällberg Chen, Evren Alici, Niklas K. Björkström, Marcus Buggert, Per Ljungman, Johan K. Sandberg, Soo Aleman, Hans-Gustaf Ljunggren
Publikováno v:
Molecular Medicine, Vol 28, Iss 1, Pp 1-12 (2022)
Abstract Adaptive immune responses have been studied extensively in the course of mRNA vaccination against COVID-19. Considerably fewer studies have assessed the effects on innate immune cells. Here, we characterized NK cells in healthy individuals a
Externí odkaz:
https://doaj.org/article/385ad681ef5c4016a17b2e4b36257493
Autor:
Tom A. Mulder, Maria L. Andersson, Lucía Peña-Pérez, Kia Heimersson, Ioanna Xagoraris, Björn E. Wahlin, Robert Månsson, Lotta Hansson, Georgios Rassidakis, Marzia Palma
Publikováno v:
HemaSphere, Vol 6, Iss 11, p e794 (2022)
In classical Hodgkin lymphoma (cHL), the malignant cells represent only a small fraction of the tumor. Yet, they orchestrate a lymphocyte-dominated tumor microenvironment (TME) that supports their survival and growth. The systemic effects of this loc
Externí odkaz:
https://doaj.org/article/cc4447832abb4e908ef84d3a2850cd88
Autor:
Björn Engelbrekt Wahlin, Ninja Övergaard, Stefan Peterson, Evangelos Digkas, Ingrid Glimelius, Ingemar Lagerlöf, Ann‐Sofie Johansson, Marzia Palma, Lotta Hansson, Johan Linderoth, Christina Goldkuhl, Daniel Molin
Publikováno v:
eJHaem, Vol 2, Iss 3, Pp 400-412 (2021)
Abstract Treatment for patients > 60 years with classical Hodgkin lymphoma (cHL) is problematic; there is no gold standard, and outcome is poor. Using the Swedish Lymphoma Registry, we analysed all Swedish patients diagnosed with cHL between 2000 and
Externí odkaz:
https://doaj.org/article/63302eca98bd48feaf9e6ae6bdbac5ba
Autor:
Jeanette Lundin, Tom A. Mulder, Magdalena Kättström, Tove Wästerlid, Anders Uddevik, Håkan Mellstedt, Kia Heimersson, Lotta Hansson, Marzia Palma, Anders Österborg
Publikováno v:
eJHaem, Vol 2, Iss 3, Pp 525-529 (2021)
Abstract Ibrutinib is used continuously in CLL. This phase 1b/2 study interim analysis explored on‐off‐repeat dosing to reduce toxicity. After 12 months, 16/22 patients (73%) remained in first off‐phase irrespective if initial CR/PR or TP53 abe
Externí odkaz:
https://doaj.org/article/7f328d6a737444259549a86a1865a7f1
Autor:
Ninja Övergaard, Kjersti Lia, Peter Asdahl, Per Wikman, Ingrid Glimelius, Ingemar Lagerlöf., Ann-Sofie Johansson, Lotta Hansson, Gunilla Enblad, Johan Linderoth, Christina Goldkuhl, Alexander Fosså, Peter Kamper, Daniel Molin
Publikováno v:
HemaSphere, Vol 6, Pp 37-38 (2022)
Externí odkaz:
https://doaj.org/article/696d5c23453f446fa253b8f28204b6af
Autor:
Tom A. Mulder, Maria L. Andersson, Lucia Peña-Pérez, Kia Heimersson, Ioanna Xagoraris, Björn E. Wahlin, Robert Månsson, Lotta Hansson, Georgios Z. Rassidakis, Marzia Palma
Publikováno v:
HemaSphere, Vol 6, Pp 15-16 (2022)
Externí odkaz:
https://doaj.org/article/df75b3c76f7d4ab7b4da4c1155415b62